SCHEDULE 13D/A: Pfizer Completes Full Divestment of Haleon Stake with Final Share Sale and Buyback

Pfizer Inc. has announced the completion of its divestment from Haleon plc, ceasing to be a beneficial owner of the consumer healthcare company's shares following a secondary offering and a share buyback.

Summary

• Pfizer Inc. has filed Amendment No. 15 to its Schedule 13D, marking its final amendment and exit filing for its beneficial ownership in Haleon plc.
• As of March 21, 2025, Pfizer no longer beneficially owns more than five percent of Haleon's Ordinary Shares, holding 0.0% of the outstanding shares.
• This divestment was executed through two primary transactions: a March 2025 Secondary Offering and a March 2025 Share Buyback.
• In the March 2025 Secondary Offering, Pfizer sold 617,553,920 Ordinary Shares at a price of 385 pence (approximately $5.01) per share.
• Concurrently, Haleon plc repurchased approximately 44 million Ordinary Shares from Pfizer in the March 2025 Share Buyback for an aggregate purchase price of approximately GBP170 million (approximately $220 million).

Sentiment

Score: 7

Explanation: The sentiment is positive as it marks the successful completion of a planned strategic separation for Pfizer and removes a significant share overhang for Haleon, which can be viewed favorably by the market.

Positives

• For Haleon: The completion of Pfizer's divestment removes a significant overhang of shares, potentially reducing selling pressure on Haleon's stock.
• For Haleon: The share buyback demonstrates Haleon's confidence in its own valuation and returns capital to shareholders (indirectly, by reducing outstanding shares).
• For Pfizer: The divestment allows Pfizer to fully separate from its consumer healthcare business, streamlining its focus on its core pharmaceutical operations and generating capital.

Negatives

• For Haleon: The exit of a major founding shareholder like Pfizer could be perceived by some as a loss of institutional backing, though this was a planned separation.
• For Pfizer: The sale of shares at a specific price might not represent the optimal valuation if the market price were to increase significantly post-sale.

Future Outlook

The document primarily details a completed transaction and Pfizer's exit from Haleon, rather than providing forward-looking statements or guidance for either company's future operations or financial performance.

Industry Context

This announcement signifies the final step in the planned separation of Pfizer's consumer healthcare business, which was spun off into Haleon. Such divestitures allow pharmaceutical companies to focus on their core drug development and prescription medicine portfolios, while the consumer health entities operate independently, often seeking growth in over-the-counter products and wellness. This trend reflects a broader industry move towards specialization.

Comparison to Industry Standards

• This filing details a specific divestment transaction rather than operational results, making direct comparisons to industry-standard financial benchmarks or competitor performance less applicable.
• The transaction structure (secondary offering and share buyback) is a common mechanism for large shareholders to exit positions in publicly traded companies.

Related Party Transactions

• The March 2025 Share Buyback involved Haleon plc purchasing shares directly from Pfizer Inc., which was a related party due to Pfizer's previous significant ownership stake. This transaction was conducted under the terms of the July 2024 Share Purchase Deed.

Stakeholder Impact

• Shareholders (Haleon): The removal of a large block of shares held by Pfizer could reduce potential selling pressure, potentially stabilizing or supporting the share price. The share buyback also reduces the number of outstanding shares, which can be accretive to earnings per share.
• Shareholders (Pfizer): Pfizer has successfully divested its remaining stake, realizing capital that can be deployed elsewhere in its core pharmaceutical business.
• Management (Haleon): The company now operates fully independently without a major founding shareholder, potentially allowing for greater strategic autonomy.

Next Steps

• This filing represents the final amendment to Pfizer's Schedule 13D for Haleon, indicating no further reporting obligations for Pfizer regarding its beneficial ownership in Haleon.
• Haleon plc will continue its operations as an independent consumer healthcare company.

Key Dates

Keywords

Haleon plc, Pfizer Inc., SEC filing, Schedule 13D, divestment, secondary offering, share buyback, consumer healthcare, beneficial ownership, exit filing, equity sale, corporate separation